Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics

Zahra Pakbaz, Theodore Wun

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Recent studies suggest that sickle cell disease (SCD) is a hypercoagulable state contributing to vaso-occlusive events in the microcirculation, resulting in acute and chronic sickle cell-related organ damage. In this article, we review the existing evidence for contribution of hemostatic system perturbation to SCD pathophysiology. We also review the data showing increased risk of thromboembolic events, particularly newer information on the incidence of venous thromboembolism. Finally, the potential role of platelet inhibitors and anticoagulants in SCD is briefly reviewed.

Original languageEnglish (US)
Pages (from-to)355-374
Number of pages20
JournalHematology/Oncology Clinics of North America
Volume28
Issue number2
DOIs
StatePublished - Apr 2014

Fingerprint

Sickle Cell Anemia
Hemostatics
Platelet Aggregation Inhibitors
Venous Thromboembolism
Microcirculation
Anticoagulants
Therapeutics
Incidence

Keywords

  • Anti-platelets
  • Anticoagulants
  • Hypercoagulable
  • Sickle cell
  • Thromboembolism

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics. / Pakbaz, Zahra; Wun, Theodore.

In: Hematology/Oncology Clinics of North America, Vol. 28, No. 2, 04.2014, p. 355-374.

Research output: Contribution to journalArticle

@article{facd50b1ea9f4757b3d857eef50963a1,
title = "Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics",
abstract = "Recent studies suggest that sickle cell disease (SCD) is a hypercoagulable state contributing to vaso-occlusive events in the microcirculation, resulting in acute and chronic sickle cell-related organ damage. In this article, we review the existing evidence for contribution of hemostatic system perturbation to SCD pathophysiology. We also review the data showing increased risk of thromboembolic events, particularly newer information on the incidence of venous thromboembolism. Finally, the potential role of platelet inhibitors and anticoagulants in SCD is briefly reviewed.",
keywords = "Anti-platelets, Anticoagulants, Hypercoagulable, Sickle cell, Thromboembolism",
author = "Zahra Pakbaz and Theodore Wun",
year = "2014",
month = "4",
doi = "10.1016/j.hoc.2013.11.011",
language = "English (US)",
volume = "28",
pages = "355--374",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics

AU - Pakbaz, Zahra

AU - Wun, Theodore

PY - 2014/4

Y1 - 2014/4

N2 - Recent studies suggest that sickle cell disease (SCD) is a hypercoagulable state contributing to vaso-occlusive events in the microcirculation, resulting in acute and chronic sickle cell-related organ damage. In this article, we review the existing evidence for contribution of hemostatic system perturbation to SCD pathophysiology. We also review the data showing increased risk of thromboembolic events, particularly newer information on the incidence of venous thromboembolism. Finally, the potential role of platelet inhibitors and anticoagulants in SCD is briefly reviewed.

AB - Recent studies suggest that sickle cell disease (SCD) is a hypercoagulable state contributing to vaso-occlusive events in the microcirculation, resulting in acute and chronic sickle cell-related organ damage. In this article, we review the existing evidence for contribution of hemostatic system perturbation to SCD pathophysiology. We also review the data showing increased risk of thromboembolic events, particularly newer information on the incidence of venous thromboembolism. Finally, the potential role of platelet inhibitors and anticoagulants in SCD is briefly reviewed.

KW - Anti-platelets

KW - Anticoagulants

KW - Hypercoagulable

KW - Sickle cell

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84896733894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896733894&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2013.11.011

DO - 10.1016/j.hoc.2013.11.011

M3 - Article

C2 - 24589271

AN - SCOPUS:84896733894

VL - 28

SP - 355

EP - 374

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -